CNJ.TO  Cangene Cp

Exchange

TSX

Sector

Life Sciences

Industry

Market Cap.

240.3M

Vuru Grade

39.25/100

Current Price

$3.60
0.00 (0.00%)

Growth Price

$4.10
Undervalued by 13.88%

Stability Price

$2.79
Overvalued by 22.48%

Company Metrics

  • 169 P/E
  • 2.08 P/S
  • 1.25 P/B
  • -0.15 EPS
  • 5.09% Cash ROIC
  • 1.68 Cash Ratio
  • 0 / 0% Dividend
  • 255,197.00 Avg. Vol.
  • 66.75M Shares
  • 240.3M Market Cap.

Company Description

Cangene Corporation develops, manufactures, and commercializes therapeutics for infectious diseases or biodefence applications in the United States, Canada, and internationally. The company develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma; and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Emergent BioSolutions, Inc. (EBS): New Analyst Report from Zacks Equity ...
NASDAQ - Aug 12, 2014
We are positive on Emergent BioSolutions' acquisition of Cangene as it has significantly expanded the company's product portfolio/pipeline. We believe that the stock is fairly valued at current levels with limited scope for upside. Consequently, we ...
US Government exercises contract options valued at $18.9M for Emergent ...
Government Security News - Aug 20, 2014
The scope of the contract, originally awarded to Cangene Corporation, which Emergent acquired in February 2014, was to maintain the ability to manufacture licensed VIGIV, with annual options to conduct additional services to support licensure ...
Regulatory Explainer: What You Need to Know About the Regulation of Ebola ...
Regulatory Focus - Aug 7, 2014
A botulism antitoxin manufactured by Cangene was approved in March 2013. In all cases, approval was based on FDA's findings that a ... Expanded access works, in general, in one of two ways: Either a company with an experimental product creates a new ...
Profits fall at Emergent BioSolutions
Gazette.Net: Maryland Community News Online - Aug 13, 2014
The company reported Friday that the Centers for Disease Control and Prevention has exercised contract options related to its treatment for complications resulting from smallpox vaccinations.
Emergent BioSolutions' (EBS) CEO Dan Abdun-Nabi on Q2 2014 Results ...
Seeking Alpha (registration) - Aug 9, 2014
9, 2014 5:15 AM ET | About: Emergent BioSolutions Inc. (EBS) by: SA Transcripts. Emergent ... During the second quarter, which was the first full quarter of combined operations with Cangene, we began to realize some of the benefits of our growth strategy.
Biotech Stock Directory Update
InvestorIdeas.com (press release) - Aug 14, 2014
Cangene Corporation (TSX:CNJ.TO) is one of Canada's largest and earliest biopharmaceutical companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba.
Trader's Recap : Emergent BioSolutions (NYSE:EBS), Conatus Pharmaceuticals ...
Tech News - Aug 12, 2014
Emergent BioSolutions Inc. (NYSE:EBS) announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration (FDA) for Anthrax Immune Globulin Intravenous (Human) [AIGIV] as part of a development contract with the ...
Analysts' Ratings Reiterations for August, 12th (BA, CI, CLI, CTL, CVS, CZR ...
Mideast Time - Aug 12, 2014
We are positive on Emergent BioSolutions' acquisition of Cangene as it has significantly expanded the company's product portfolio/pipeline. We believe that the stock is fairly valued at current levels with limited scope for upside. Consequently, we ...